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Prevalence of Bacteremia and Bacterial Meningitis in Febrile
Neonates and Infants in the Second Month of Life
A Systematic Review and Meta-analysis
Eric A. Biondi, MD, MS; Brian Lee, PhD; Shawn L. Ralston, MD, MS; Jared M. Winikor, MD; Justin F. Lynn, MD, MPH; Angela Dixon, BSN, MLS; Russell McCulloh, MD

Abstract

Key Points

IMPORTANCE Febrile neonates (persons in the first month of life) are believed to be at higher risk
for bacteremia or bacterial meningitis than infants in their second month of life. However, the true
prevalence is unclear.

Question Are febrile neonates (in the
first month of life) at higher risk for
bacteremia and bacterial meningitis
than febrile infants in their second

OBJECTIVE To determine modern rates of bacteremia and bacterial meningitis in febrile neonates

month of life?
Findings This systematic review and

and infants in the second month of life presenting to an ambulatory setting.

meta-analysis including 15 713 culture

DATA SOURCES A comprehensive, no-limit search was conducted in PubMed using previously

results from 12 studies found a

published search terms in February 2015 and repeated in September 2016.

significant difference in the prevalence
of bacteremia (2.9%) and bacterial

STUDY SELECTION Abstracts and full texts were reviewed independently by several investigators.

meningitis (1.2%) in febrile neonates vs

Studies were included if data regarding blood cultures or cerebrospinal fluid cultures from

the prevalence of bacteremia (1.6%) and

consecutive febrile infants in an ambulatory setting could be extrapolated within the age groups. To

bacterial meningitis (0.4%) in febrile

limit the analysis to the period after the availability of the Haemophilus influenzae type b vaccination,

infants in their second month of life.

studies that collected data before 1990 were excluded.

Meaning Febrile neonates may have
roughly twice the rate of bacteremia and

DATA EXTRACTION AND SYNTHESIS Data were extracted in accordance with the Meta-analyses
of Observational Studies in Epidemiology (MOOSE) reporting guidelines via independent abstraction
by several investigators. The Newcastle-Ottawa Scale was used to assess bias.

meningitis as febrile infants in their
second month of life, although overall
rates in both groups are low.

MAIN OUTCOMES AND MEASURES The primary outcomes were prevalence rates of bacteremia
and bacterial meningitis in febrile neonates and infants in the second month of life. In neonates,
prevalence rates were also estimated in the era of group B Streptococcus intrapartum antibiotic
prophylaxis (after 1996).

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

RESULTS In total, 7264 abstracts were screened, resulting in 188 full-text manuscripts reviewed,
with 12 meeting inclusion criteria (with 15 713 culture results). For febrile neonates, the prevalence of
bacteremia was 2.9% (95% CI, 2.3%-3.7%; I2 = 50%; n = 5145) and the prevalence of bacterial
meningitis was 1.2% (95% CI, 0.8%-1.9%; I2 = 27%; n = 3288). In neonates in the era after group B
Streptococcus prophylaxis, the prevalence of bacteremia was 3.0% (95% CI, 2.3%-3.9%; I2 = 6%;
n = 2055) and the prevalence of meningitis was 1.0% (95% CI, 0.4%-2.1%; I2 = 28%; n = 1739). For
febrile infants in the second month of life, the prevalence of bacteremia was 1.6% (95% CI,
0.9%-2.7%; I2 = 78%; n = 4778) and the prevalence of meningitis was 0.4% (95% CI, 0.2%-1.0%;
I2 = 33%; n = 2502).
(continued)
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Abstract (continued)

CONCLUSIONS AND RELEVANCE These findings suggest that febrile neonates have approximately
twice the rate of bacteremia and meningitis as febrile infants in their second month of life.
JAMA Network Open. 2019;2(3):e190874. doi:10.1001/jamanetworkopen.2019.0874

Introduction
The diagnosis and management of fever of an unknown source in infants represent a common clinical
conundrum encountered by pediatricians, family medicine practitioners, and emergency medicine
clinicians.1,2 For decades, it has been generally accepted practice that neonates (persons in the first
month of life) with fever of an unknown source, given the assumption that they are at relatively high
risk of bacteremia and meningitis, should undergo empirical and invasive evaluations that include
laboratory work, lumbar puncture, antibiotics, and hospitalization pending the exclusion of bacterial
infection via microbiological culture results.1-6 Infants in the second month of life who present with
fever of an unknown source are generally considered to be at lower risk for bacterial infection than
febrile neonates and therefore more amenable to risk stratification in their care plan.1,3,7
In a review on the management of fever in infants, the Agency for Healthcare Research and
Quality highlighted a paucity of knowledge surrounding the stratification of risk of bacteremia or
meningitis by age group.1 Furthermore, most commonly used risk stratification criteria were
published decades ago,5 and in 1996, the Centers for Disease Control and Prevention published
recommendations for the prevention of perinatal group B Streptococcus (GBS) that markedly
reduced the incidence of early-onset GBS disease in neonates, one of the most common causes of
bacteremia and meningitis in this age group.8
The primary objective of the present review was to estimate and compare the prevalence of
bacteremia and meningitis in febrile neonates and infants in the second month of life. The secondary
objective was to estimate and compare the prevalence of bacteremia and meningitis in febrile
neonates prior to and after implementation of intrapartum GBS prophylaxis.

Methods
The protocol for this review is registered with PROSPERO (protocol number CRD42015015996), the
international prospective register of systematic reviews.9 This study followed the Meta-analyses of
Observational Studies in Epidemiology (MOOSE) reporting guideline (eAppendix and eTable in the
Supplement).10

Search Strategy
A medical librarian (A.D.) conducted a comprehensive search in PubMed in February 2015 using a
previously published combination of Medical Subject Headings and keywords (eAppendix in the
Supplement).1 No limits were applied, and a total of 6792 citations were retrieved. Additional studies
were identified through hand searching and manual searching of the bibliographies of qualifying
studies, particularly those of other systematic reviews. Non-English articles were translated to
English using translation software. Just prior to analysis, a second search was performed in
September 2016 to ensure that new studies were included in the analysis. An additional 469 citations
were retrieved. In the case of papers that did not meet criteria for inclusion due to lack of available
data, the corresponding authors were contacted via email to determine whether additional data
were available.

Study Selection
Studies were considered eligible for inclusion if they met the following criteria: evaluated febrile
infants for bacteremia or meningitis using blood cultures or cerebrospinal fluid (CSF) cultures;
JAMA Network Open. 2019;2(3):e190874. doi:10.1001/jamanetworkopen.2019.0874 (Reprinted)
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included consecutive febrile infants during the study date range (eg, studies identifying infants via
discharge diagnosis codes were not included); included only infants seen in an ambulatory setting (ie,
emergency department or outpatient clinic); allowed data abstraction within age groups
representing neonates and infants in the second month of life; used blood culture or CSF culture
results to determine the presence or absence of bacteremia or meningitis; provided the total number
of consecutive febrile infants and the total number of those infants who had blood cultures or CSF
cultures within the 2 age groups; had the intention to perform blood cultures or CSF cultures on all
eligible infants in an age category (eg, a study would not be included if it was left to physician
discretion whether or not to obtain CSF); and collected data in the developed world. Studies were
excluded if data collection or enrollment began before 1990 to limit the analysis to the era after
implementation of Haemophilus influenzae type b vaccination.11
When it was stated within a paper that it was standard policy at the study location to obtain a
certain workup on all febrile infants of a certain age (eg, all febrile infants <30 days of age have CSF
cultures obtained), then it was assumed that all febrile infants received that workup unless otherwise
stated within the paper. Likewise, if it was stated in a paper that the standard of care was to
hospitalize all febrile infants of a certain age, then the infants in that age group were included in the
review even if the paper reported outcomes only for “hospitalized” infants.

Identification and Data Extraction
All abstracts were screened by the study investigators for potential inclusion. Each full-text article
from abstracts that had the potential to meet inclusion criteria was then reviewed independently by
at least 2 study investigators (E.A.B., J.F.L., and R.M.), and consensus regarding inclusion was
determined prior to data abstraction. For full-text articles meeting criteria, data abstraction occurred
independently by 2 study investigators (E.A.B. and R.M.) who then discussed their findings to arrive
at consensus. Any discrepancies were resolved by consensus of additional study investigators.

Quality Assessment
Studies were assessed for bias using the Newcastle-Ottawa Scale (NOS) for nonrandomized studies,
a tool recommended by the Cochrane Collaborative.12 The NOS assigns a certain number of “stars”
to the potential for bias in 3 areas in each study, with more stars indicating less likelihood of bias:
selection of groups (maximum 4 stars), comparability of groups (maximum 2 stars), and the
determination of outcomes (maximum 3 stars). The stars can be added together to produce an
overall assessment of bias. The data of interest to the present systematic review were often not the
primary or secondary outcomes of the included papers; thus, the items on the scale were scored on
the estimated quality of the design relative to the data of interest to this review rather than on the
quality of the original study design (ie, we did not score an individual study on the basis of their
original design because our population of interest and study outcome of interest may have been
different from that of the original study; instead, scores were determined based on how the study
included patients in our cohort of interest, whether patients with central venous catheters were
excluded, etc). In addition, because the data of interest required aspects of cohort and case-control
design, each study was evaluated on the item from the most applicable scale (the cohort scale was
used to determine study quality regarding selection and comparability, whereas the case-control
scale was used to determine study quality regarding exposure). Within the selection subsection,
studies that did not obtain cultures on all infants were only awarded a maximum of 3 stars. For the
comparability subsection, studies were awarded 1 star if they attempted to control for contaminants
(eg, defined contaminants a priori) and a second star if they attempted to control for risk status
above that of the general febrile infant population (eg, excluded infants with central venous
catheters). Two study investigators (E.A.B. and R.M.) independently applied the NOS to the included
studies and then discussed each score to arrive at consensus.
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Statistical Analysis
Fixed- and random-effects estimates were calculated based on inverse-variance, logit transformation
of the proportion of meningitis and bacteremia cases. The exact binomial interval method was used
for calculating 95% CIs, which accommodates studies in which zero events were reported. The level
of heterogeneity was determined based on the I2 statistic, including corresponding 95% CIs. Given
the level of heterogeneity observed, the random-effects results are reported within the text and
figures. Differential summary estimates based on the cohort year were hypothesized, and
consequently stratified estimates are reported. All eligible studies were included in this main analysis.
To estimate potential differences in the proportions of bacteremia and meningitis cases by age
group, subgroup analysis was performed for neonates in the first month of life vs infants in the
second month of life. Statistical significance was defined by nonoverlapping confidence intervals.
An a priori subgroup analysis both before and after the GBS prophylaxis era was also performed
for neonates, with studies reporting a data collection period that included 1996 or earlier specified
as before prophylaxis, and studies reporting a data collection period beginning after 1996 specified
as after prophylaxis. Two studies3,13 included data collected both before and after 1996, and these
were designated as before prophylaxis to provide as pure a sample as possible in the modern era of
GBS prophylaxis.
A subgroup analysis of the era before and after 7-valent pneumococcal conjugate vaccine
(PCV7) was performed to determine whether there was a detectable change in bacteremia or
meningitis rates after the introduction of the vaccine. The date of data collection for this analysis was
2001, with data collected during or after 2001 included in the after-PCV7 cohort.
An a priori sensitivity analysis was performed to assess the association with prevalence and
heterogeneity by removing studies that did not attempt to control for risk. Because prevalence is
reported rather than effect estimates (eg, odds ratios, risk ratios, etc), the potential for publication
biases was not directly assessed; instead, the proportions and associated standard errors were relied
on to address the issue. All analyses were completed using the meta package in R, version 3.3.2 (R
Foundation).

Results
In total, 7264 unique articles were screened by abstract, resulting in the full-text review of 188
articles. Of these, 18 met criteria for inclusion; however, 6 of these were excluded because
participants were enrolled before 1990, which left 12 studies included in the final qualitative and
quantitative analysis (Figure 1). The most common reason for full-text exclusion (97 of 176 of
excluded texts) was the lack of breakout of bacteremia or meningitis prevalence by age group.

Qualitative Analysis
Of the 12 included studies, 7 took place in the United States.3,13-18 Eleven studies provided data for
the neonatal analysis,3,13,15-23 and 5 studies provided data for older infants.3,13,14,17,22 Additional
unpublished data from 3 papers were provided by the original authors to allow inclusion of these
studies.3,22,23 The analyzed studies are described in the Table, including years of data collection,
setting, relevant inclusion/exclusion criteria for the individual study, and outcomes pertinent to the
present review.
Overall NOS scores ranged from 7 to 9 (maximum score, 9) for the 12 included studies (Table).
Scores within individual categories for each study are provided in the eTable in the Supplement.

Quantitative Analysis
Data from 15 713 blood cultures and CSF cultures were included in this analysis. Analysis of
bacteremia prevalence for all neonates and infants in the second month of life included 9923 children
from 12 studies. Random-effects modeling estimated the prevalence of bacteremia in the first 2
months of life to be 2.4% (95% CI, 1.8%-3.1%; I2 = 72%) (Figure 2A). The meningitis analysis for the
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first 2 months of life included 5790 infants from 8 studies. Random-effects modeling estimated the
prevalence of bacterial meningitis in the first 2 months of life to be 0.9% (95% CI, 0.5%-1.5%;
I2 = 55%) (Figure 2B).
The bacteremia analysis for the first month of life included 5145 neonates from 11 studies. Five
of these studies (2055 neonates) collected all data after 1996. Random-effects modeling of all
studies estimated the prevalence of bacteremia in febrile neonates to be 2.9% (95% CI, 2.3%-3.7%;
I2 = 50%) (Figure 3A). When only studies containing data from the GBS prophylaxis era (after 1996)
were analyzed, the rate of bacteremia remained 3.0% (95% CI, 2.3%-3.9%; I2 = 6%) (Figure 3A).
The meningitis analysis for the first month of life included 3288 neonates from 7 studies. Four
of these studies (1739 neonates) collected all data after 1996. Random-effects modeling of all studies
estimated the prevalence of meningitis in febrile neonates to be 1.2% (95% CI, 0.8%-1.9%; I2 = 27%)
(Figure 3B). When only studies containing data from the GBS prophylaxis era (after 1996) were
included, the prevalence of meningitis was 1.0% (95% CI, 0.4%-2.1%; I2 = 28%) (Figure 3B).
The bacteremia analysis for the second month of life included 4778 infants from 5 studies.
Random-effects modeling estimated the prevalence of bacteremia in febrile infants in the second
month of life to be 1.6% (95% CI, 0.9%-2.7%; I2 = 78%) (Figure 4A).
The bacterial meningitis analysis for the second month of life included 2502 infants from 3
studies. Random-effects modeling estimated the prevalence of bacterial meningitis in febrile infants
in the second month of life to be 0.4% (95% CI, 0.2%-1.0%; I2 = 33%) (Figure 4B).
Our before- and after-PCV7 analysis did not identify statistically significant before and after
differences in rates of bacteremia in the first month of life (95% CI, 1.9%-4.2% [I2 = 66%] vs 95% CI,
2.4%-4.0% [I2 = 0%], respectively) or meningitis in the first month of life (95% CI, 0.8%-2.3%
[I2 = 24%] vs 95% CI, 0.2%-2.5% [I2 = 52%], respectively). For bacteremia in the second month of
life, there was only 1 study performed in the period after PCV7, and for meningitis in the second
month, none were performed.

Sensitivity Analyses
The sensitivity analysis removing studies that did not attempt to control for risk above that of the
general population of febrile neonates resulted in a bacteremia prevalence estimate of 3.1% (95% CI,

Figure 1. Flowchart of Eligible Studies
7261 Articles identified via database searching

3 Articles identified through other sources

7264 Unique articles screened

7076 Articles excluded

188 Full-text articles reviewed

176 Records excluded
97 No age breakout
47 Wrong population
10 Not original research
7 Did not use cultures for diagnosis
6 Contained pre-1990 data
5 Duplicate data
4 No fever criteria

12 Articles included in qualitative synthesis

12 Articles included in quantitative synthesis
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Table. Description of Included Studies
Date

Design

Setting

Symptoms of Population

Data on Prevalence (% of Patients)a

Scoreb

Chiu et al,19 1994

1992-1993

P, C

ED (Taiwan)

Temperature ≥38.0°C;
previously healthyc

0-31 d: All 254 had blood culture,
13 B (5)d

9

Bonsu et al,13 2003

1992-1999

R, C

ED

Rectal temperature
≥38.0°C in ED or home

Study (n = 3961), 151 excluded for
missing data, 1353 aged >56 d; 0-28 d:
all 950 had blood culture, 14 B (2);
29-56 d: all 1507 had blood culture,
17 B (1)

7

Chiu et al,20 1997

1994-1995

P, C

ED (Taiwan)

Temperature ≥38.0°C;
previously healthyc

0-28 d: All 250 had blood culture,
11 B (4)d

9

Garcia et al,22 2012e

2003-2010

R, C

ED (Spain)

Rectal temperature
≥38.0°C in ED or home

0-28 d: 207 of 307 had blood culture, 8
B (4)d; 29-56 d: 620 of 641 had blood
culture, 21 B (3)d

8

Study
Bacteremia-only studies

No obvious source of fever
No respiratory symptoms
No diarrhea
Meningitis-only studies
None
Bacteremia and meningitis
studies
Ferrera et al,18 1997

1990-1994

R, C

ED

Temperature ≥38.0°C in ED
or home
No obvious infectious
source

Bonadio et al,

14

1993

0-28 d: (n = 188), 167 (89) had blood
8
culture and 148 (79) had CSF culture, 6 B
(4), 4 M (3); B/M concurrence not
reportedf
9

1991-2000

P, C

ED

Rectal temperature
≥38.0°C in ED or home

28-56 d: All 534 had blood culture and
CSF culture, 7 B (1), 4 M (1); no
concurrent B/M

Bachur and Harper,3 2001e

1993-1999

R, C

ED

Rectal temperature
≥38.0°Cc

0-30 d: (n = 1298), 1215 (94) had blood 8
culture and 1147 (88) had CSF culture,
26 B (2), 10 M (1); B/M concurrence not
reported. 31-60 d: (n = 2104), 1866
(89) had blood culture and 1717 (82)
had CSF culture, 19 B (1), 4 M (0); B/M
concurrence not reported

Baker and Bell,15 1999

1994-1996

P, C

ED

Rectal temperature
≥38.0°Cc

3-28 d: All 254 had blood culture and
CSF culture, 8 B (3), 4 M (2); 3
concurrent B/M

8

Herr et al,17 2001

1999-2000

R, C

ED

Temperature ≥38.0°Cc

0-28 d: (n = 179), 13 excluded for
missing data, all remaining 166 had
blood culture and CSF culture, 1B (1), 2
M (1); no concurrent B/M; 29-60 d:
(n = 285), 17 excluded for missing data,
all remaining 268 had blood culture and
CSF culture, 6 B (2), 0 M (0)

8

Caviness et al,16 2008

2001-2005

R, C

ED

Rectal temperature
≥38.0°C in ED

0-28 d: (n = 960), 893 (93) had blood
culture and 874 (91) had CSF culture, 30
B (3), 13 M (1)g; B/M concurrence not
reported

6

Zarkesh et al,21 2011

2004-2009

R, C

ED (Iran)

Temperature ≥38.5°C in ED

0-28 d: (n = 253), 51 excluded for
incomplete records, all remaining 202
had blood culture and CSF culture, 8 B
(4), 1 M (0); 1 concurrent B/M

8

No prior admission
Full term
No chronic disease
No recent antibiotics
Ashkenazi-Hoffnung
et al,23 2011e

2005-2009

P, C

Pediatric department
(Israel, unclear if ED
or clinic)

Rectal temperature
≥38.0°Cc
No chronic disease

Study (n = 1584) of febrile infants aged 9
≤90 d, but only those aged 0-28 d were
consecutive; 0-28 d: all 510 had blood
culture and CSF culture, 12 B (2), 0 M (0)

Born >34 wk
No recent antibiotics
Abbreviations: B, bacteremia; C, consecutively enrolled patients; CSF, cerebrospinal
fluid; ED, emergency department; M, meningitis; P, prospective; R, retrospective.
a

Percentages are rounded to nearest integer.

b

Newcastle-Ottawa Scale bias scores range from 1 (worst) to 9 (best).

c

Unclear whether this status needed to be during evaluation or if it could have been at
home as well.

d

Unable to use CSF culture data owing to inability to identify the total number of CSF
cultures obtained or owing to potential selection bias (eg, CSF culture obtained only if
clinical suspicion for meningitis).

e

Additional unpublished data obtained via correspondence with original authors.

f

There were 724 infants presenting in the ED; 43 incomplete records were excluded; of
the remaining 681 infants, 188 had fever without an obvious source, 21 had
undocumented blood culture, and 40 had undocumented CSF culture.

g

There may have been 12 of 874 (1%); unclear owing to rounding in the fluid cultures of
the original study.

JAMA Network Open. 2019;2(3):e190874. doi:10.1001/jamanetworkopen.2019.0874 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 12/03/2020

March 22, 2019

6/12

JAMA Network Open | Pediatrics

Bacteremia and Bacterial Meningitis Prevalence in Febrile Neonates and Infants

2.3%-4.2%; I2 = 44%; n = 3048) and a bacterial meningitis prevalence estimate of 1.0% (95% CI,
0.5%-2.2%; I2 = 46%; n = 2160) for neonates. These estimates were not significantly different from
the full analysis or the after-GBS prophylaxis era analysis. The sensitivity analysis of febrile infants in
the second month of life, removing studies that did not attempt to control for risk above that of the
general population of febrile infants, resulted in a bacteremia prevalence estimate of 1.7% (95% CI,

Figure 2. Meta-analysis of Prevalence of Bacteremia and Meningitis in Febrile Neonates and Infants in the First and Second Months of Life
A Prevalence of bacteremia

Earliest
Year

No. of Events per
Total No. of Infants

Prevalence, %
(95% CI)

Chiu et al,19 1994

1992

13/254

5.1 (2.8-8.6)

6.8

Chiu et al,20 1997

1994

11/250

4.4 (2.2-7.7)

6.5

Zarkesh et al,21 2011

2004

4.0 (1.7-7.7)

5.8

Ferrera et al,18 1997

1990

8/202
6/167

3.6 (1.3-7.7)

5.2

Caviness et al,16 2008

2001

30/893

3.4 (2.3-4.8)

8.1

Baker and Bell,15 1999

1994

8/254

3.1 (1.4-6.1)

5.8

Garcia et al,22 2012

2003

8/297

2.7 (1.2-5.2)

5.8

Ashkenazi-Hoffnung et al,23 2011

2005

12/510

2.4 (1.2-4.1)

6.7

Bachur and Harper,3 2001

1993

26/1215

2.1 (1.4-3.1)

7.9

Bonsu et al,13 2003

1992

14/950

1.5 (0.8-2.5)

7.0

Herr et al,17 2001

1999

1/153

0.7 (0.0-3.6)

1.6

2.9 (2.3-3.7)

67.2

Study

Weight, %

First Month

Random-effects model
Heterogeneity: I2 = 50%, P = .03
Second Month
Garcia et al,22 2012

2003

21/620

3.4 (2.1-5.1)

7.6

Herr et al,17 2001

1999

5/251

2.0 (0.6-4.6)

4.8

Bonadio et al,14 1993

1991

7/534

1.3 (0.5-2.7)

5.6

Bonsu et al,13 2003

1992

17/1507

1.1 (0.7-1.8)

Bachur and Harper,3 2001

1993

19/1866

1.0 (0.6-1.6)

7.3
7.5

1.6 (0.9-2.7)

32.8

2.4 (1.8-3.1)

100.0

Random-effects model
Heterogeneity: I2 = 78%, P < .01
Random-effects model
Heterogeneity: I2 = 72%, P < .01

0

2

4

6

8

10

Prevalence, % (95% CI)
B

Prevalence of meningitis

Study

Earliest
Year

No. of Events per
Total No. of Infants

Prevalence, %
(95% CI)

Weight, %

First Month
Ferrera et al,18 1997

1990

4/148

2.7 (0.7-6.8)

11.8

Baker and Bell,15 1999

1994

4/254

1.6 (0.4-4.0)

11.9

Caviness et al,16 2008

2001
1999

1.4 (0.7-2.4)
1.3 (0.2-4.6)

16.9

Herr et al,17 2001

12/874
2/153

Bachur and Harper,3 2001

1993

10/1147

0.9 (0.4-1.6)

16.3

Zarkesh et al,21 2011

2004

1/202

0.5 (0.0-2.7)
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0.9%-3.4%; I2 = 81%; n = 3271) and a bacterial meningitis prevalence estimate of 0.4% (95% CI,
0.2%-1.0%; I2 = 33%; n = 2502). These estimates were similar to those of the full analysis.

Discussion
We present robust and largely homogeneous pooled prevalence estimates for bacteremia and
bacterial meningitis in neonates and infants in the second month of life with fever presenting for
ambulatory evaluation. We are unaware of large, previously published data estimating these rates.
Health care professionals may use these data as reasonable estimates of pretest probability during
clinical decision making. Accurate estimates of pretest probability are necessary for optimal
performance of clinical prediction rules and risk calculators.

Figure 3. Meta-analysis of Prevalence of Bacteremia and Meningitis in Febrile Neonates in the First Month of Life
A Prevalence of bacteremia
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In the cohort of febrile neonates, our subanalysis of studies in the era after GBS prophylaxis
(Figure 3) did not produce different estimates of prevalence but did resolve the excess heterogeneity
observed in the after-GBS neonatal bacteremia cohort when compared with the entire cohort of
neonatal bacteremia studies (I2 = 6% vs 50%, respectively). Thus, the pooled prevalence from this
subanalysis is more likely to accurately reflect a sample of modern neonates with fever as well as the
current risk of bacteremia in this population. The heterogeneity observed in the neonatal meningitis
analysis was relatively low in the overall neonatal meningitis cohort and the after-GBS prophylaxis
cohort (I2 = 27% and 28%, respectively).
Similarly, although the data are somewhat older, the bacterial meningitis analysis of infants with
fever in the second month of life did not show excess heterogeneity (I2 = 33%). Therefore, we
suggest that this analysis is more likely to reflect the true prevalence of bacterial meningitis in this
population.
The analysis of bacteremia in febrile infants in the second month of life showed substantial
heterogeneity (I2 = 78%) that we were unable to resolve through sensitivity analyses by risk.
Although our analysis may provide the most thorough prevalence estimate available, the potential
inconsistencies within the data reduce the confidence we can ascribe to them, rendering us unable to
suggest that these data accurately reflect current rates of bacteremia in this population.24
With regard to the clinical evaluation of febrile neonates and infants, presentation in the first vs
the second month of life often serves as a branch point used by clinicians to decide whether or not
to perform a lumbar puncture or to hospitalize the patient or both.1,5 Our pooled prevalence estimate
of the rate of bacterial meningitis in febrile neonates in the era after GBS prophylaxis was 1.0%,
whereas the estimate in febrile infants in the second month of life was 0.4%. Although this outcome
is roughly twice the rate of meningitis in the younger age group, it is unclear whether such a
difference in pretest probability obviates the need to perform a lumbar puncture in older infants. The
absolute risk difference of 4 per 1000 translates to an extra 250 lumbar punctures per case of
meningitis in older infants.

Figure 4. Meta-analysis of Prevalence of Bacteremia and Meningitis in Febrile Infants in the Second Month of Life
A Prevalence of bacteremia
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Implicit in our study is the assumption that risk of bacteremia or bacterial meningitis decreases
around 30 days of age, and our data support such an assessment. Comparing our prevalence
estimates for bacteremia and meningitis by age subgroup suggests that this distinction may be
relevant. However, we a priori adopted this age division for our analyses because this age
stratification has served for decades as a commonly used clinical standard for decision
making.1,4,5,23,25 There may be a more meaningful age stratification (eg, <7 days of life); however, the
paucity of data does not currently allow for robust estimates to be made outside of the cut point of
1 month of age.1
Only 6 of the 12 included studies attempted, in some way, to control for risk of bacterial
infection. Thus, although the clinical diagnostic and management conundrums for physicians are
often with regard to well-appearing febrile infants, our analysis includes some ill-appearing infants,
creating the potential for our pooled analysis to overestimate prevalence rates in well-appearing
febrile infants. We can be somewhat reassured, however, that our sensitivity analysis excluding
papers that did not provide any attempt to adjust for risk did not identify a significant change in our
prevalence estimates (defined by wide overlap in the confidence intervals). That said, we suggest
that our prevalence estimates be considered a “ceiling” when it comes to well-appearing febrile
infants rather than be considered a true assessment of risk in that population.

Strengths and Limitations
Our study has several strengths. First, the quality of the included papers for our outcomes of interest
was high. Second, a rigorous no-filter search approach, responses to personal communications with
a number of corresponding authors, and inclusion of studies examining only consecutive febrile
neonates or infants enabled us to provide relatively precise pooled prevalence estimates. Third, our
outcomes of interest—positive blood cultures and CSF cultures—function as objective criterion
standard measures of bacteremia and bacterial meningitis.
Our study also has limitations. The majority of articles included in this review did not use “fever
without a source” as a specific inclusion criterion, and it is possible that this factor resulted in an
overestimate of prevalence in this population. The vast majority of studies were performed in the
emergency department; therefore, our estimates may not be representative of other clinical areas
(eg, outpatient clinics). Regarding the before- and after-GBS prophylaxis subanalysis, it is unclear
what, if any, uptake the United States–based recommendation for antibiotic prophylaxis had
internationally, particularly regarding data from other countries included in our analysis. Finally, we
identified no studies meeting our criteria published within the last 5 years. It is unclear how, or
whether, current prevalence rates might differ from those of the published data.

Conclusions
The results of this systematic review and meta-analysis suggest that the rates of bacteremia and
meningitis in febrile neonates are about twice that of infants in the second month of life.
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